hVIVO CEO Mo Khan on company's expansion and upcoming capital markets day

Proactive - Interviews for investors

hVIVO PLC chief executive Yamin 'Mo' Khan joined Proactive's Stephen Gunnion with details of recent developments, including a change of address, the upcoming capital markets day, and new major contracts. Khan shared that hVIVO has moved to a new facility at Canary Wharf, now home to the world's largest human challenge trial unit. The capital markets day, set for July 17th, will feature a trading update and tours of the new laboratory and quarantine facilities. Khan also highlighted hVIVO's largest field study contract to date, a Phase 2b influenza trial with a US-based company. This trial will enrol up to 1,000 healthy volunteers in both the US and UK, with significant revenue expected in 2025. Differentiating between field studies and human challenge trials, Khan explained that the former allows volunteers to go home post-vaccination, unlike the quarantine requirement of challenge trials. In discussing service diversification, Khan noted the expansion of laboratory services and new ventures into patient recruitment and consulting services. Additionally, hVIVO plans to convert its former corporate office into an expanded outpatient unit by early Q4, enhancing its capacity for screening and field trials. For more insights from hVIVO and updates on their latest projects, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to our channel, and enable notifications for future content. #hVIVO #MoKhan #CapitalMarketsDay #ClinicalTrials #MedicalResearch #InfluenzaTrial #HealthcareInnovation #BiotechNews #ProactiveInvestors #LabServices #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews